Why Is PULSE BIOSCIENCES IN (PLSE) Stock Up Today?

Pulse Biosciences stock surged 8.57% to $52.97 in a single session driven by a new buy rating from Freedom Capital. The medical device company saw renewed investor attention after the firm initiated coverage with a Buy rating and a $73 price target. The stock opened with a small gap up and traded within a volatile range before settling near the session low.

What Happened

Freedom Capital’s initiation of coverage with a Buy rating marked a key catalyst for the move. The firm cited the company’s growth potential, signaling confidence in its long-term trajectory. This followed a broader trend of analyst upgrades in the health care sector, as seen in recent coverage that highlighted several stocks for potential volatility. Pulse Biosciences CEO and other executives have not publicly commented on the rating, but the COO, Liane Rae Teplitsky, has made two recent purchases totaling $200K, indicating insider confidence. The stock’s performance was also featured in several health care-focused updates, which emphasized its inclusion in a list of stocks expected to show significant movement.

What The Data Shows

The stock has a market cap of $3.5B and is currently unprofitable with an EPS of -1.18 for the trailing twelve months. Its beta of 1.62 suggests it is more volatile than the broader market. The 52-week range spans from $12.56 to $58.90, with the stock currently near the upper end. On the intraday session, PLSE opened at $53.36 and reached a high of $54.42 before declining to a low of $52.50. The session ended at $52.63 with no unusual volume activity reported so far.

What To Watch

Investors should monitor the stock for any follow-up analyst commentary or coverage breadth in the coming days. No earnings date is currently scheduled, but continued analyst upgrades or downgrades could influence near-term momentum.